In a separate experiment, we found that TSC2-null LAM patient-derived cells expressed much higher levels of IGFBP2 compared with TSC2-reexpresing cells (Figure 3A), indicating that TSC2 negatively regulates IGFBP2 expression. The gene discussed is IGFBP2; the disease is lymphangioleiomyomatosis.